AR072545A1 - Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. - Google Patents
Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias.Info
- Publication number
- AR072545A1 AR072545A1 ARP090102453A ARP090102453A AR072545A1 AR 072545 A1 AR072545 A1 AR 072545A1 AR P090102453 A ARP090102453 A AR P090102453A AR P090102453 A ARP090102453 A AR P090102453A AR 072545 A1 AR072545 A1 AR 072545A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- optionally substituted
- hydroxy
- amino
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000001363 autoimmune Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 27
- 229910052736 halogen Inorganic materials 0.000 abstract 24
- 150000002367 halogens Chemical class 0.000 abstract 24
- 125000003545 alkoxy group Chemical group 0.000 abstract 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 12
- 125000001188 haloalkyl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- -1 nitro, amino Chemical group 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- BMGVFXUMEAYBAO-UHFFFAOYSA-N 5-phenyl-1h-pyrazin-2-one Chemical class N1C(=O)C=NC(C=2C=CC=CC=2)=C1 BMGVFXUMEAYBAO-UHFFFAOYSA-N 0.000 abstract 1
- 235000019227 E-number Nutrition 0.000 abstract 1
- 239000004243 E-number Substances 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de 5-fenil-1H-pirazin-2-ona que inhiben la Btk. Los compuestos aquí descritos son utiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Los compuestos son utiles además para tratar enfermedades inflamatorias y autoinmunes asociadas con una proliferacion aberrante de las células B, por ejemplo la artritis reumatoide. Describen también composiciones que contienen los compuestos de las fámulas (1) - (5) y por lo menos un vehículo, diluyente o excipiente. Reivindicacion 1: Un compuesto de las formulas (1), (2), (3), (4) o (5) en las que R es H, -R1, -R1-R2-R3, -R1-R3 o -R2-R3; R1 es arilo, heteroarilo, cicloalquilo o heterocicloalquilo, y está opcionalmente sustituido por uno o más R1'; cada R1' es con independencia alquilo inferior, hidroxi, hidroxialquilo inferior, alcoxi inferior, halogeno, nitro, amino, cicloalquilo, cicloalquil-alquilo inferior, heterocicloalquilo, ciano, nitro o haloalquilo inferior; R2 es -C(=O), -C(=O)O, -(CH2)qC(=O)O, -C(=O)N(R2')2, -(CH2)q, -O(CH2)q, -CH2C(=O), -CH2C(=O)N(R2')2 o -S(=O)2; en los que cada R2' es con independencia H, alquilo inferior, alcoxi inferior, haloalquilo inferior o hidroxialquilo inferior; y q es e numero 1, 2 o 3; R3 es H o R4; dicho R4 es alquilo inferior, heteroalquilo inferior, alcoxi inferior, amino, arilo, arilalquilo, alquilarilo, heteroarilo, alquil-heteroarilo, heteroaril-alquilo, cicloalquilo, alquil-cicloalquilo, cicloalquil-alquilo, heterocicloalquilo, alquil-heterocicloalquilo o heterocicloalquil-alquilo, y está opcionalmente sustituido por uno o más alquilo interior, hidroxi, oxo, hidroxialquilo inferior, alcoxi inferior, halogeno, nitro, amino, ciano, alquilsulfonilo inferior o haloalquilo inferior; Q es CH2, CH(Y') o NH; en el que Y' es halogeno, hidroxi o alquilo inferior, dicho alquilo inferior está opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por hidroxi, alcoxi inferior, amino y halogeno; Y1 es H o alquilo inferior; Y2 es Y2a o Y2b; dicho Y2a es H o halogeno; Y2b es alquilo inferior opcionalmente sustituido por uno o más Y2b'; dicho Y2b' es hidroxi, alcoxi inferior o halogeno; cada Y2' es con independencia Y2'a o Y2'b; dicho Y2'a es halogeno; Y2'b es alquilo inferior, opcionalmente sustituido por uno o más Y2'b'; dicho Y2'b' es hidroxi, alcoxi inferior o halogeno; n es el numero 0, 1, 2 o 3; Y3 es halogeno o alquilo inferior, dicho alquilo inferior está opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por hidroxi, alcoxi inferior, amino y halogeno; m es el numero 0 o 1; Y4 es Y4a, Y4b, Y4c o Y4d; en los que Y4a es H o halogeno; Y4b es alquilo inferior opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por haloalquilo inferior, halogeno, hidroxi, amino y alcoxi inferior; Y4c es cicloalquilo inferior opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por alquilo inferior, haloalquilo inferior, halogeno, hidroxi, amino y alcoxi inferior; e Y4d es amino opcionalmente sustituido por uno o más alquilo inferior; o una sal farmacéuticamente aceptable del mismo. En una forma de ejecucion, la solicitud proporciona un compuesto de la formula (1), en la que: R es H, -R1, -R1-R2-R3, -R1-R3 o -R2-R3; R1 es arilo, heteroarilo, cicloalquilo o heterocicloalquilo, y está opcionalmente sustituido por uno o más R1'; cada R1' es con independencia alquilo inferior, hidroxi, hidroxialquilo inferior, alcoxi inferior, halogeno, nitro, amino, cicloalquilo, heterocicloalquilo, ciano, nitro o haloalquilo inferior; R2 es -C(=O), -C(=O)O, -C(=O)N(R2'), -(CH2)q, -O(CH2)q, -(CH2)qC(=O)O, -O(CH2)qC(=O)N(R2'), -CH2C(=O)N(R2') o -S(=O)2; dicho R2' es H o alquilo inferior; y q es el numero 1, 2 o 3; R3 es H o R4; dicho R4 es alquilo inferior, alcoxi inferior, amino, arilo, arilalquilo, alquilarilo, heteroarilo, alquil-heteroarilo, heteroaril-alquilo, cicloalquilo, alquil-cicloalquilo, cicloalquil-alquilo, heterocicloalquilo, alquil-heterocicloalquilo o heterocicloalquilalquilo, y está opcionalmente sustituido por uno o más alquilo inferior, hidroxi, oxo, hidroxialquilo inferior, alcoxi inferior, halogeno, nitro, amino, ciano alquilsulfonilo inferior o haloalquilo interior; Q es CH o N; Y1 es H o alquilo inferior; Y2 es Y2a o Y2b; dicho Y2a es H o halogeno; Y2b es alquilo inferior, opcionalmente sustituido por uno o más Y2b'; dicho Y2b' es hidroxi, alcoxi inferior o halogeno; cada Y2' es con independencia Y2'a o Y2'b; dicho Y2'a es halogeno; Y2'b es alquilo inferior, opcionalmente sustituido por uno o más Y2'b'; dicho Y2'b' es hidroxi, alcoxi inferior o halogeno; n es el numero 0, 1, 2 o 3; Y3 es halogeno o alquilo inferior, dicho alquilo inferior está opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por hidroxi, alcoxi inferior, amino y halogeno; m es el numero 0 o 1; Y4 es Y4a, Y4b, Y4c o Y4d;en los que Y4a es H o halogeno; Y4b es alquilo inferior opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por haloalquilo inferior, halogeno, hidroxi, amino y alcoxi inferior; Y4c es cicloalquilo inferior opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por alquilo inferior, haloalquilo inferior, halogeno, hidroxi, amino y alcoxi inferior; e Y4d es amino opcionalmente sustituido por uno o más alquilo inferior; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7751008P | 2008-07-02 | 2008-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072545A1 true AR072545A1 (es) | 2010-09-08 |
Family
ID=40940244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102453A AR072545A1 (es) | 2008-07-02 | 2009-07-01 | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8536166B2 (es) |
| EP (1) | EP2300459B1 (es) |
| JP (1) | JP5490789B2 (es) |
| KR (2) | KR101523451B1 (es) |
| CN (1) | CN102083819B (es) |
| AR (1) | AR072545A1 (es) |
| AU (1) | AU2009265813B2 (es) |
| BR (1) | BRPI0913879A2 (es) |
| CA (1) | CA2728683C (es) |
| CL (1) | CL2010001608A1 (es) |
| CY (1) | CY1114223T1 (es) |
| DK (1) | DK2300459T3 (es) |
| ES (1) | ES2420854T3 (es) |
| HR (1) | HRP20130698T1 (es) |
| IL (1) | IL209729A0 (es) |
| MX (1) | MX2010013478A (es) |
| PE (1) | PE20110164A1 (es) |
| PL (1) | PL2300459T3 (es) |
| PT (1) | PT2300459E (es) |
| RU (1) | RU2507202C2 (es) |
| SI (1) | SI2300459T1 (es) |
| TW (1) | TWI401083B (es) |
| WO (1) | WO2010000633A1 (es) |
| ZA (1) | ZA201008808B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| EP2421854B1 (en) * | 2009-04-24 | 2014-07-23 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| RU2017112518A (ru) * | 2010-05-07 | 2019-01-25 | Джилид Коннектикут, Инк. | Пиридоновые и азапиридоновые соединения и способы применения |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| WO2012031004A1 (en) * | 2010-09-01 | 2012-03-08 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, method of making, and method of use thereof |
| AU2012282229B2 (en) | 2011-07-08 | 2015-05-07 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| JP5976828B2 (ja) * | 2011-11-03 | 2016-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物 |
| TWI553004B (zh) | 2011-11-03 | 2016-10-11 | 建南德克公司 | ８－氟基呔－１（２ｈ）－酮化合物 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
| US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
| CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| CA2881761A1 (en) * | 2012-09-13 | 2014-03-20 | Christine E. Brotherton-Pleiss | Inhibitors of bruton's tyrosine kinase |
| WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| WO2014125410A1 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | N-substituted heterocyclic derivatives as kinase inhibitors |
| US9556147B2 (en) | 2013-03-05 | 2017-01-31 | Hoffmann-La Inc. | Inhibitors of bruton's tyrosine kinase |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| MX367918B (es) | 2013-04-25 | 2019-09-11 | Beigene Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. |
| CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
| CN104211703B (zh) * | 2013-05-30 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类作为布鲁顿激酶抑制剂的稠杂环化合物 |
| MX2015018038A (es) * | 2013-07-03 | 2016-03-16 | Hoffmann La Roche | Compuestos de heteroaril-piridona y aza-piridona-amida. |
| DK3026050T3 (en) * | 2013-07-26 | 2019-02-18 | Carna Biosciences Inc | NEW TRIAZINE DERIVATIVE |
| PL3027618T3 (pl) | 2013-07-30 | 2021-04-19 | Kronos Bio, Inc. | Polimorf inhibitorów syk |
| PL3027171T3 (pl) | 2013-07-30 | 2020-08-24 | Gilead Connecticut, Inc. | Formulacja inhibitorów syk |
| CN112457403B (zh) | 2013-09-13 | 2022-11-29 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| RU2646758C2 (ru) | 2013-12-05 | 2018-03-07 | Ф. Хоффманн-Ля Рош Аг | Гетероарил пиридоны и азапиридоны с электрофильной функциональностью |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| EP3042903B1 (en) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| CN109071496B (zh) | 2016-03-31 | 2021-07-30 | 武田药品有限公司 | 异喹啉基三唑酮复合物 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| KR20230162137A (ko) | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
| CN118252927A (zh) | 2016-08-19 | 2024-06-28 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| KR20190058550A (ko) | 2016-09-19 | 2019-05-29 | 메이 파마, 아이엔씨. | 병용 요법 |
| EP3544975B1 (en) * | 2016-11-22 | 2022-01-05 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and use |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| KR102399996B1 (ko) | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| EP3927708A1 (en) | 2019-02-22 | 2021-12-29 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69918422T2 (de) * | 1998-03-14 | 2005-08-11 | Altana Pharma Ag | Phthalazinone als PDE3/4 Inhibitoren |
| SG126007A1 (en) * | 2000-09-15 | 2006-10-30 | Anormed Inc | Chemokine receptor binding hetrocyclic compounds |
| DE602004005881T2 (de) * | 2003-10-14 | 2008-01-17 | Pharmacia Corp. | Substituierte pyrazinonverbindungen zur behandlung von entzündungen |
| TW200716551A (en) * | 2005-03-10 | 2007-05-01 | Cgi Pharmaceuticals Inc | Certain substituted amides, method of making, and method of use thereof |
| WO2006124731A2 (en) | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| RU2008108898A (ru) | 2005-08-09 | 2009-09-20 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназы |
| EP1919905B1 (en) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
| US7691885B2 (en) | 2005-08-29 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| AU2006284900A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
| AU2006287480B2 (en) * | 2005-09-09 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| CN101405001A (zh) * | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
| CA2650611A1 (en) | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
| US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| PE20081370A1 (es) | 2006-09-11 | 2008-11-28 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| AR063706A1 (es) * | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| JP2010502751A (ja) * | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| ES2499017T3 (es) | 2007-10-23 | 2014-09-26 | F. Hoffmann-La Roche Ag | Nuevos inhibidores de quinasa |
| CN102066366B (zh) * | 2008-06-24 | 2014-04-16 | 霍夫曼-拉罗奇有限公司 | 新型取代的吡啶-2-酮和哒嗪-3-酮 |
| JP5635535B2 (ja) * | 2009-01-08 | 2014-12-03 | レスバーロジックス コーポレイション | 心血管疾患の予防および治療のための化合物 |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
-
2009
- 2009-06-22 CN CN200980125623.9A patent/CN102083819B/zh not_active Expired - Fee Related
- 2009-06-22 DK DK09772333.2T patent/DK2300459T3/da active
- 2009-06-22 ES ES09772333T patent/ES2420854T3/es active Active
- 2009-06-22 WO PCT/EP2009/057707 patent/WO2010000633A1/en active Application Filing
- 2009-06-22 EP EP09772333.2A patent/EP2300459B1/en not_active Not-in-force
- 2009-06-22 BR BRPI0913879A patent/BRPI0913879A2/pt not_active IP Right Cessation
- 2009-06-22 SI SI200930631T patent/SI2300459T1/sl unknown
- 2009-06-22 JP JP2011515329A patent/JP5490789B2/ja not_active Expired - Fee Related
- 2009-06-22 MX MX2010013478A patent/MX2010013478A/es active IP Right Grant
- 2009-06-22 PE PE2010001208A patent/PE20110164A1/es not_active Application Discontinuation
- 2009-06-22 RU RU2011103234/04A patent/RU2507202C2/ru not_active IP Right Cessation
- 2009-06-22 PL PL09772333T patent/PL2300459T3/pl unknown
- 2009-06-22 PT PT97723332T patent/PT2300459E/pt unknown
- 2009-06-22 AU AU2009265813A patent/AU2009265813B2/en not_active Expired - Fee Related
- 2009-06-22 CA CA2728683A patent/CA2728683C/en not_active Expired - Fee Related
- 2009-06-22 KR KR1020137016860A patent/KR101523451B1/ko not_active IP Right Cessation
- 2009-06-22 KR KR1020107029738A patent/KR101320763B1/ko not_active IP Right Cessation
- 2009-06-30 TW TW098122087A patent/TWI401083B/zh not_active IP Right Cessation
- 2009-07-01 US US12/459,595 patent/US8536166B2/en not_active Expired - Fee Related
- 2009-07-01 AR ARP090102453A patent/AR072545A1/es not_active Application Discontinuation
-
2010
- 2010-12-02 IL IL209729A patent/IL209729A0/en unknown
- 2010-12-07 ZA ZA2010/08808A patent/ZA201008808B/en unknown
- 2010-12-29 CL CL2010001608A patent/CL2010001608A1/es unknown
-
2013
- 2013-07-23 HR HRP20130698AT patent/HRP20130698T1/hr unknown
- 2013-08-01 CY CY20131100661T patent/CY1114223T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| AR070408A1 (es) | Piridinonas y piridazinonas | |
| AR082590A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR072272A1 (es) | Piridin-2-onas y piridazin-3-onas sustituidas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias causadas por una activacion aberrante de las celulas b, y composiciones farmaceuticas que las contienen. | |
| AR086403A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR076066A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR074459A1 (es) | Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
| AR060792A1 (es) | Ligandos de gucorticoides, metodos para prepararlos, composiciones farmaceuticas, y usos de los mismos | |
| AR080525A1 (es) | Un proceso usando reactivos de grignard | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| CO5650231A2 (es) | Derivados de 1-(alquilaminoalquil-pirrolidin-/piperidinil)-2,2-difenilacetamida como antagonistas del receptor muscarinico, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
| ECSP088378A (es) | Derivados de piperazina útiles como antagonistas de ccr5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |